Claims for Patent: 10,206,930

Summary for Patent: 10,206,930

Title:	Methods for treating T-cell acute lymphoblastic leukemia
Abstract:	The present invention is directed to methods of treating T-ALL that involve administering an inhibitor of jumonji D3 (JMJD3) demethylase. Another embodiment of the invention relates to methods inhibiting T-ALL cell proliferation and/or survival that involves administering an inhibitor of jumonji D3 (JMJD3) demethylase to a population of T-ALL cells.
Inventor(s):	Aifantis; Iannis (Brooklyn, NY), Ntziachristos; Panagiotis (New York, NY)
Assignee:	New York University (New York, NY)
Application Number:	15/237,049
Patent Claims:	1. A method of treating T-cell acute lymphoblastic leukemia in a subject, said method comprising: selecting a subject having T-cell acute lymphoblastic leukemia and administering, to the selected subject, an inhibitor of jumonji D3 (JMJD3) demethylase activity at a dosage effective to treat the T cell acute lymphoblastic leukemia in the subject. 2. The method of claim 1, wherein the selected subject has an activating NOTCH1 mutation. 3. The method according to claim 1, wherein the JMJD3 inhibitor is ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-- 4-yl)amino)propanoate (GSK-J4) or a derivative thereof. 4. The method according to claim 1, wherein the JMJD3 inhibitor is a JMJD3 antisense RNA, shRNA, or siRNA oligonucleotide. 5. The method according to claim 1 further comprising: administering a chemotherapeutic agent to the subject in combination with said JMJD3 inhibitor. 6. The method according to claim 5, wherein the chemotherapeutic agent is selected from the group consisting of cytarabine, vincristine, prednisone, doxorubicin, daunorubicin, PEG asparaginase, methotrexate, cyclophosphamide, L-asparaginase, etoposide, and leucovorin. 7. The method according to claim 1, wherein said administering is repeated periodically. 8. The method according to claim 1, wherein T-cell acute lymphoblastic leukemia is adult T-cell acute lymphoblastic leukemia. 9. The method according to claim 1, wherein T-cell acute lymphoblastic leukemia is pediatric T-cell acute lymphoblastic leukemia. 10. A method of inhibiting T-cell acute lymphoblastic leukemia cell proliferation and/or survival, said method comprising: administering to a population of T-cell acute lymphoblastic leukemia cells an inhibitor of JMJD3 at a dosage effective to inhibit the T-cell acute lymphoblastic leukemia cell proliferation and/or survival. 11. The method according to claim 10, wherein the JMJD3 inhibitor is ethyl 3-((6-(4,5-dihydro-1H-benzo[d] azepin-3 (2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate (GSK-J4) or a derivative thereof. 12. The method according to claim 10, wherein the JMJD3 inhibitor is a JMJD3 antisense RNA, shRNA, or siRNA oligonucleotide. 13. The method according to claim 10, wherein said administering is carried out in vivo. 14. The method according to claim 10, wherein said administering is repeated periodically.

Details for Patent 10,206,930

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-03-15